TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01611129

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based counseling
Description: Stage 1 - introduction to the concept of the patient journey and presenting the participants series of questions which may help them to explore their journey through hearing loss; Stage 2 - patient journey model of PHI and 2 case examples will be presented. The PHI will be advised to compare their journey to the model presented and identify the similarities and differences; Stage 3 - communication partners' journey model will be presented and the PHI will be asked to consider how interactions between each other may affect various things in the physical, mental and social domains; and Stage 4 - patients will be encouraged to think about how the PHI \& CP may influence each other during their journey through hearing loss, how they can overcome some of the difficulties they may be experiencing and to think about the potential benefits and the challenges from the audiological management.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet-based counseling
Description: Stage 1 - introduction to the concept of the patient journey and presenting the participants series of questions which may help them to explore their journey through hearing loss; Stage 2 - patient journey model of PHI and 2 case examples will be presented. The PHI will be advised to compare their journey to the model presented and identify the similarities and differences; Stage 3 - communication partners' journey model will be presented and the PHI will be asked to consider how interactions between each other may affect various things in the physical, mental and social domains; and Stage 4 - patients will be encouraged to think about how the PHI \& CP may influence each other during their journey through hearing loss, how they can overcome some of the difficulties they may be experiencing and to think about the potential benefits and the challenges from the audiological management.
Study: NCT01981278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol ER 250-mg TRF tablet
Description: Participants will receive single oral dose of tapentadol ER 250-mg TRF tablet on Day 1 of each treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol ER 250-mg PR2 tablet
Description: Participants will receive single oral dose of tapentadol PR2 250-mg tablet on Day 1 of each treatment period.
Study: NCT01894477

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow Transplantation
Description: Undergo allogeneic bone marrow transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow Transplantation
Description: Undergo allogeneic bone marrow transplant
Study: NCT02304913

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Study: NCT02683902

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: The electrodes will be placed at the same positions as in active stimulation; however, the device will be turned off after 30 s of stimulation.
Study: NCT02176915

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Print Materials
Study: NCT04524988

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Simulation Training
Description: All participants underwent 2.5h of training with one of two laparoscopic simulation trainers (FLS or EMIG).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Simulation Training
Description: All participants underwent 2.5h of training with one of two laparoscopic simulation trainers (FLS or EMIG).
Study: NCT04925141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib Tablets
Description: Tyrosine Kinase Inhibitor (TKI)
Study: NCT06446570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab,Tremelimumab
Description: Durvalumab: 1.5g Q4W plusTremelimumab: 75mg Q4W up to 4cycle then Durvalumab 750mg Q2W, till PD or unacceptable toxicity.
Study: NCT03481439

Intervention type: OTHER
Intervention: Collection of a Pharmaceutical intervention
Description: collection of pharmaceutical interventions carried out by the pharmaceutical team in the care uni in Primary and secondary cohort

Intervention type: OTHER
Intervention: Collection of a Pharmaceutical intervention
Description: collection of pharmaceutical interventions carried out by the pharmaceutical team in the care uni in Primary and secondary cohort
Study: NCT01100112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: One Budesonide-MMX 9 mg tablet will be taken in the morning after breakfast for 8 weeks.
Study: NCT02304913

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary recommendations
Study: NCT01301716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0980
Description: Oral escalating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0980
Description: Oral escalating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0980
Description: Oral escalating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Intravenous repeating dose
Study: NCT04870866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide ribonucleoside
Description: Two year intervention
Study: NCT02012517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prolonged antibiotic treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Short antibiotic course (standard of care)
Study: NCT02660229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone Hydrochloride
Description: Oxycodone injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulphate
Description: Morphine sulphate injection
Study: NCT03618537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib at a fixed dose of 4mg on days 1, 8, and 15 of a 28-day cycle. Ixazomib will be given orally on days 1, 8, and 15 of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 4mg-12mg will be allowed on days 1, 8, 15 if patients previously tolerated dexamethasone without issue.
Study: NCT01892566

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth Intervention
Description: See arm description
Study: NCT00309218

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Description: withdrawal of methylprednisolone in arm A and continuous Steroid Treatment in arm B

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methylprednisolone
Description: withdrawal of methylprednisolone in arm A and continuous Steroid Treatment in arm B
Study: NCT03479983

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AMX160
Description: 500 mg Phyllanthus emblica L. fresh fruit extract capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500 mg roasted rice powder in visually identical capsules
Study: NCT01517984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus (CNI) Withdrawal
Description: Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.~Subjects without any clinical acute rejection (AR) in the first 6 months, without borderline or acute rejection on the 6 month biopsy, and without donor-specific antibody (DSA) at anytime, including the 6 month test will be randomized (2:1) to tacrolimus (CNI) withdrawal.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Immunosuppressive Therapy
Description: Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Immunosuppressive Therapy
Description: Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.
Study: NCT01658046

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Description: Bilateral quadriceps NMES using a four-channel portable electrical stimulator. Biphasic symmetric constant current impulses with a pulse width 300 µs, a frequency of 50 Hz, and duty cycle of 10 s on and 20 s off was applied for 20 min per day, 2 days per week for 10 weeks.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Endurance training
Description: Endurance training consists of 30 minutes of aerobic exercise (15 minutes on treadmill and 15 minutes on stationary bicycle) at 80% of maximal heart rate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endurance training
Description: Endurance training consists of 30 minutes of aerobic exercise (15 minutes on treadmill and 15 minutes on stationary bicycle) at 80% of maximal heart rate

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Quadriceps strength training
Description: Quadriceps resistance training was applied using free weights for 2 days per week for 10 weeks according to 1 repetition maximum, starting at 45% for two sets.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quadriceps strength training
Description: Quadriceps resistance training was applied using free weights for 2 days per week for 10 weeks according to 1 repetition maximum, starting at 45% for two sets.
Study: NCT01092884

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Polypodium leucotomos extract
Description: 240 mg capsule of Polypodium leucotomos extract will be taken orally three times daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This placebo capsule will be taken orally three times daily
Study: NCT00992550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cigarette

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cigarette

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hookah

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hookah
Study: NCT03800550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Description: Bedaquiline tablet will be administered, orally.
Study: NCT01301716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: intravenous repeating dose
Study: NCT01894477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Intravenously administered Fludarabine Phosphate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Intravenously administered Fludarabine Phosphate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo allogeneic PBSC transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo allogeneic PBSC transplant

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treosulfan
Description: Intravenously administered Treosulfan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treosulfan
Description: Intravenously administered Treosulfan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative Studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative Studies
Study: NCT04274660

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DWELL (Diabetes and WELLbeing) Programme
Description: 12-week psychoeducational programme
Study: NCT02504268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Study: NCT03800550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Description: Bedaquiline tablet will be administered, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Clarithromycin tablet will be administered, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Clarithromycin tablet will be administered, orally.
Study: NCT03773809

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D capsule
Description: The intervention was given by oral administration of vitamin D3 capsule each of which contains 40000 IU of vitamin D3. The capsule was manufactured and supplied by Beximco Pharmaceutical Limited, Bangladesh. The placebo was also be manufactured and supplied by the same pharmaceutical company and was similar in size shape \& appearance to vitamin D3 capsule but contained all the ingredients of vitamin D capsule other than the vitamin D3

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D capsule
Description: The intervention was given by oral administration of vitamin D3 capsule each of which contains 40000 IU of vitamin D3. The capsule was manufactured and supplied by Beximco Pharmaceutical Limited, Bangladesh. The placebo was also be manufactured and supplied by the same pharmaceutical company and was similar in size shape \& appearance to vitamin D3 capsule but contained all the ingredients of vitamin D capsule other than the vitamin D3

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral administration of placebo
Study: NCT01301716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Intravenous repeating dose
Study: NCT03773809

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral administration of placebo
Study: NCT03526263

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastric mucosal devitalization
Description: During routine laparoscopic sleeve gastrectomy surgery, once the greater curvature of the stomach is excised as per normal surgical technique, the investigators will take the specimen out and perform an ablation ex-vivo, with the intention of performing selective mucosal devitalization. This specimen will then be transported to pathology lab for analysis.
Study: NCT01912235

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 2-15N glutamine
Description: Glutamine with N15 isotope tracer

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 15N2 arginine and 15N proline
Description: Arginine and Proline isotope tracers

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1-13C glutamine
Description: Glutamine carbon isotope tracer
Study: NCT03588754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Propranolol Extended Release (160mg/day).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill administered orally.
Study: NCT01301716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: intravenous repeating dose
Study: NCT00502736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibandronate [Bondronat]
Description: 6mg iv on days 1-3
Study: NCT01475721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADVAIR 100/50mcg
Description: fluticasone propionate/salmeterol combination (100/50mcg) twice daily (AM and PM) for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADVAIR 250/50mcg
Description: fluticasone propionate/salmeterol combination (250/50mcg) twice daily (AM and PM) for 6 months
Study: NCT00651105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Study: NCT01475721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADVAIR 500/50mcg
Description: fluticasone propionate/salmeterol combination (500/50mcg) twice daily (AM and PM) for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FLOVENT 100mcg
Description: fluticasone propionate (100) twice daily (AM and PM) for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FLOVENT 250mcg
Description: fluticasone propionate (250mcg) twice daily (AM and PM) for 6 months
Study: NCT00443092

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: proprietary cherry juice blend (food)
Description: 2 bottles per day for 6 weeks, 1 in the morning and 1 in the evening

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control juice (kool aid blend)
Description: 2 bottles per day for 6 weeks, 1 in the morning and 1 in the evening
Study: NCT03985904

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ART THERAPY
Description: ART THERAPY: Nursing Interventions Classification = 4330 Weekly 2 hour group carried out by a mental health nurse, a social monitor and a museum educator.
Study: NCT04079946

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Mesocolic Excision with Central Vessel Ligation
Description: sharp dissection of the anatomical layers and the dissection of the visceral plane from the parietal one . In addition a central division of the feeding arteries at their origins is performed at the level of superior mesenteric artery for tumors of the right colon and at the level of inferior mesenteric artery or the aorta for tumors of the left colon .this allows for removal of the maximum number of lymph nodes possible.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional surgery of cancer colon
Description: removal of the tumor with no ligation of the vessel centrally or removal of the whole mesocolon
Study: NCT03424200

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Routine care
Description: Participants will receive routine care

Intervention type: OTHER
Group type: OTHER
Intervention: Coaching plus routine care
Description: Participants will receive coaching plus routine care
Study: NCT02158273

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: 145 mg/day, oral pill, 9 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TRICOR (fenofibrate)
Description: 145 mg/day, oral pill, 9 days
Study: NCT01622231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate
Description: 55 mcg/day, intranasal, 12 weeks
Study: NCT00726869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elotuzumab (HuLuc63)
Description: Cohort 1 - 2.5 mg/kg elotuzumab IV with bortezomib on Days 1 \& 11, with only Bortezomib IV on Days 4 \& 8; Cohort 2 - 5.0 mg/kg elotuzumab IV with bortezomib on Days 1 \& 11, with only Bortezomib IV on Days 4 \& 8; Cohort 3 - 10.0 mg/kg elotuzumab IV withbortezomib on Days 1 \& 11, with only Bortezomib IV on Days 4 \& 8; and Cohort 4 - 20.0 mg/kg elotuzumab IV with bortezomib on Days 1 \& 11, with only Bortezomib IV on Days 4 \& 8.
Study: NCT00651105

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03733522

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rubber dam isolation
Description: Local anesthesia, use of dental clamp and rubber dam, followed by restoration using universal adhesive system and bulkfill composite restoration

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Relative isolation
Description: No local anesthesia, use of cotton rollers and saliva ejector, followed by restoration using universal adhesive system and bulkfill composite restoration
Study: NCT02860286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene.
Study: NCT04707729

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ROX index algorithm
Description: The thresholds of the ROX index for intubation are the following:~* After 2 hours of HFNC: ROX \<2.85.~* After 4 and 6 hours of HFNC: ROX \<3.47~* After 8, 10 and 12 hours of HFNC: ROX \<3.85 If the ROX index is between the abovementioned thresholds and 4.88, the NHF support will be also increased to the maximum tolerated flow (up to 60L/min) and FIO2 of 1 and subsequently titrated with the target SpO2. If the patient is already treated with to 60L/min) and FIO2 of 1 and no further increase could be done and the ROX index will be recalculated after 30 minutes of full NHF support. The ROX index will be recalculated in 30 minutes: 1) if the ΔROX is \<0 the patient will be intubated; 2) if the ΔROX is 0-0.5, the ΔROX will be reassessed in 20 minutes; and 3) if the ΔROX is \>0.5 the patient will not be intubated, NHF will be managed as protocolized and respiratory condition will be reassessed every two hours or at any new clinical deterioration.
Study: NCT04125433

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Integrated Care Services
Description: The project employs a two level intervention to include Peer Support Specialist (PSS) and Community Health Advocate (CHA). Contact and engagement with participating members will be through both direct intervention in the emergency department as well as in the community for prevention visits and follow up. Peers and Community Health Advocates will address Behavioral and Social Determinants of Health (SDoH) concerns through a coordinated intervention supported by a common IT Medicaid member tracking platform. This research project will determine the feasibility of deploying a single shared IT platform that will include referral, appointment completion, and intervention outcome data. Project staff will develop a relationship with the members improving member access and engagement with community-based services. The project will determine the impact on total cost of care through redirecting study participants to community resources rather than return visits to the emergency department.
Study: NCT01354769

Intervention type: DEVICE
Intervention: CapnoStream20
Description: The monitor used for data gathering is a CapnoStream20-multi parameter monitor

Intervention type: DEVICE
Intervention: CapnoStream20
Description: The monitor used for data gathering is a CapnoStream20-multi parameter monitor
Study: NCT02296463

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV F Vaccine with adjuvant (0.5mL injection)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV F Vaccine with adjuvant (0.5mL injection)
Study: NCT02936687

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Glucose Tolerance Test
Description: The subject will drink distilled deionized water (300ml) containing 75 grams glucose within 5 minutes.